To see all protocols that comply with the WHO Essential Medicine List 

Welcome to eviQ

A free resource of evidence-based, consensus driven cancer treatment protocols and information for use at the point of care. eviQ is developed for the Australian context and supports health professionals in the delivery of cancer treatments.

Find out more

 

Latest news

View all news

From 1 June 2021 Avastin® (bevacizumab) will no longer be available on the PBS, and Mvasi® a biosimilar brand of bevacizumab will be the sole brand available on the PBS. Please note that the rapid infusion administration instructions for subsequent doses of bevacizumab included in eviQ protocols are based on studies conducted using Avastin® (bevacizumab).

The International Consensus Guideline for Anti-cancer Drug Dosing in Kidney Dysfunction is a project led by eviQ and the Cancer Institute NSW. See our dedicated webpage for more information.

Expressions of interest are invited for two eviQ Medical Oncology Reference Committee Co-Chairs. Click the link to find out details. EOIs close by COB Thursday 1st July 2021.

Join us for a free 90-minute webinar on Wednesday 21 July from 7pm-8.30pm AEST to support your understanding of the new evidence for CVAD management. The webinar will guide you through new clinical tools, eLearning, supportive resources and competency assessments.